Log In
Print
BCIQ
Print
Print this Print this
 

TK (HSV-TK) (formerly TBI-0301)

  Manage Alerts
Collapse Summary General Information
Company MolMed S.p.A.
DescriptionDonor lymphocytes engineered to express human herpes simplex thymidine kinase suicide gene
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentRegistration
Standard IndicationLeukemia
Indication DetailsFacilitate immune reconstitution in acute leukemia patients receiving haploidentical hematopoietic stem cell transplantation (HSCT); Treat leukemia
Regulatory Designation

U.S. - Orphan Drug (Facilitate immune reconstitution in acute leukemia patients receiving haploidentical hematopoietic stem cell transplantation (HSCT));
EU - Orphan Drug (Facilitate immune reconstitution in acute leukemia patients receiving haploidentical hematopoietic stem cell transplantation (HSCT));
EU - Standard Review (Facilitate immune reconstitution in acute leukemia patients receiving haploidentical hematopoietic stem cell transplantation (HSCT))

Partner

Takara Bio Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today